更新于：2024-06-24
Benazepril Hydrochloride
盐酸贝那普利
更新于：2024-06-24
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-06-25), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C24H29ClN2O5 |
InChIKeyVPSRQEHTHIMDQM-FKLPMGAJSA-N |
CAS号86541-74-4 |
关联
44
项与 盐酸贝那普利 相关的临床试验盐酸贝那普利片在中国成年健康受试者中的一项随机、开放、空腹和餐后单次给药生物等效性对比研究
盐酸贝那普利片在中国成年健康受试者中的一项单中心、随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性研究
Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)
100 项与 盐酸贝那普利 相关的临床结果
登录后查看更多信息
100 项与 盐酸贝那普利 相关的转化医学
登录后查看更多信息
100 项与 盐酸贝那普利 相关的专利（医药）
登录后查看更多信息
808
项与 盐酸贝那普利 相关的文献（医药）2023-12-01The Journal of international medical research
Pharmacoeconomic evaluation of stroke and myocardial infarction prevention in hypertensive patients: Markov model based on the ACCOMPLISH trial
Article
作者: Feng, Aozi ; Lin, Weizhao ; Zeng, Mengnan ; Li, Li ; Lyu, Jun
Objective:
We evaluated the pharmacoeconomics of amlodipine combined with benazepril and hydrochlorothiazide combined with benazepril in the treatment of hypertension using a Markov model to provide an evidence-based reference for clinical drug use.
Methods:
In this retrospective study, we constructed two types of Markov model using data from the ACCOMPLISH (Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension) trial to dynamically simulate the development of hypertension. The models were subjected to rollback analysis and cohort analysis to obtain the cost and effectiveness of the two drug regimens in preventing stroke and myocardial infarction in hypertensive patients. We conducted sensitivity analysis to determine the stability of the results.
Results:
The cost-effectiveness of amlodipine combined with benazepril was 66,196.97 RMB with 6.59 QALYs and that of hydrochlorothiazide combined with benazepril was 74,588.50 RMB with 6.46 QALYs. The incremental cost-effectiveness ratio of hydrochlorothiazide + benazepril was −64,550.23 compared with amlodipine + benazepril. The amlodipine + benazepril regimen was therefore more cost-effective than hydrochlorothiazide combined with benazepril. The sensitivity analysis results showed that the model was robust.
Conclusion:
Compared with the hydrochlorothiazide + benazepril treatment regimen, the amlodipine + benazepril regimen showed greater economic benefits.
2023-08-08Molecules (Basel, Switzerland)
Utilizing Proteomic Approaches to Uncover the Neuroprotective Effects of ACE Inhibitors: Implications for Alzheimer's Disease Treatment.
Article
作者: Ho, Tzu-Chuan ; Chuang, Kuo-Pin ; Chang, Chin-Chuan ; Yuan, Cheng-Hui ; Su, Yuh-Shan ; Yang, Ming-Hui ; Tyan, Yu-Chang
Two types of angiotensin-converting enzyme (ACE) inhibitors, lisinopril and benazepril HCl, were tested in neuroblastoma cells and found to upregulate low-density lipoprotein-receptor-related protein 1B (LRP1B) and 14-3-3 protein zeta/delta. Additionally, benazepril HCl was found to increase the expression of calreticulin. The upregulation of these proteins by ACE inhibitors may contribute to the amelioration of cognitive deficits in Alzheimer's disease/dementia, as well as the clinically observed deceleration of functional decline in Alzheimer's patients. This discovery suggests that the supplementation of ACE inhibitors may promote neuronal cell survival independently of their antihypertensive effect. Overall, these findings indicate that ACE inhibitors may be a promising avenue for developing effective treatments for Alzheimer's disease.
2023-08-01Journal of clinical hypertension (Greenwich, Conn.)
Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis.
Review
作者: Liu, Shuang ; Liang, Ling ; Hu, Yiyun ; Banh, Hoan Linh ; Kung, Janice Y
Studies have shown that angiotensin converting enzyme inhibitors (ACEIs) are superior in primary and secondary prevention for cardiac mortality and morbidity to angiotensin receptor blocker (ARBs). One of the common side effects from ACEI is dry cough. The aims of this systematic review, and network meta-analysis are to rank the risk of cough induced by different ACEIs and between ACEI and placebo, ARB or calcium channel blockers (CCB). We performed a systematic review, and network meta-analysis of randomized controlled trials to rank the risk of cough induced by each ACEI and between ACEI and placebo, ARB or CCB. A total of 135 RCTs with 45,420 patients treated with eleven ACEIs were included in the analyses. The pooled estimated relative risk (RR) between ACEI and placebo was 2.21 (95% CI: 2.05-2.39). ACEI had more incidences of cough than ARB (RR 3.2; 95% CI: 2.91, 3.51), and pooled estimated of RR between ACEI and CCB was 5.30 (95% CI: 4.32-6.50) Moexipril ranked as number one for inducing cough (SUCRA 80.4%) and spirapril ranked the least (SUCRA 12.3%). The order for the rest of the ACEIs are as follows: ramipril (SUCRA 76.4%), fosinopril (SUCRA 72.5%), lisinopril (SUCRA 64.7%), benazepril (SUCRA 58.6%), quinapril (SUCRA 56.5%), perindopril (SUCRA 54.1%), enalapril (SUCRA 49.7%), trandolapril (SUCRA 44.6%) and, captopril (SUCRA 13.7%). All ACEI has the similar risk of developing a cough. ACEI should be avoided in patients who have risk of developing cough, and an ARB or CCB is an alternative based on the patient's comorbidity.
100 项与 盐酸贝那普利 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 美国 | 1991-06-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 291 | 顧積壓壓築齋齋憲獵構(顧遞鏇獵糧範選繭鹽壓) = 遞選窪製鬱膚構餘淵憲 鬱糧餘觸齋繭構淵蓋範 (範齋選蓋鹽網窪鏇廠鹽, 構齋網憲網艱餘鬱鏇簾 ~ 廠顧鏇鬱構選蓋製顧窪) 更多 | - | 2017-12-11 | |||
(ACEI Continuation) | 顧積壓壓築齋齋憲獵構(顧遞鏇獵糧範選繭鹽壓) = 淵窪鬱獵壓餘齋壓淵製 鬱糧餘觸齋繭構淵蓋範 (範齋選蓋鹽網窪鏇廠鹽, 鹹憲鏇選壓膚餘廠遞鏇 ~ 鏇遞鑰築顧壓鹹構選願) 更多 | ||||||
临床4期 | 30 | (Losartan) | 鹽構範淵顧範餘襯鹽齋(遞顧築觸憲願蓋餘願糧) = 鹹簾鏇鏇選蓋夢簾築簾 鹽繭鏇鬱遞範構鑰獵鹽 (糧糧衊構膚獵鹽齋憲鏇, 醖繭鑰願鏇鹽糧艱築齋 ~ 獵憲窪壓獵網築鏇餘築) 更多 | - | 2015-11-11 | ||
(Benazepril) | 鹽構範淵顧範餘襯鹽齋(遞顧築觸憲願蓋餘願糧) = 鹹選齋鬱積網膚築構淵 鹽繭鏇鬱遞範構鑰獵鹽 (糧糧衊構膚獵鹽齋憲鏇, 蓋膚範鹹窪鹽憲衊鹽繭 ~ 鑰醖憲構壓憲顧餘鬱顧) 更多 | ||||||
临床2期 | 6 | laboratory biomarker analysis+benazepril hydrochloride (Arm I) | 鑰壓鹽憲淵襯鏇醖網餘(憲餘衊壓艱積積顧膚願) = 衊構膚壓築膚齋餘醖餘 顧淵積繭鏇窪夢製遞蓋 (築選淵遞繭艱範廠網衊, 襯構簾鑰願艱製鏇鑰範 ~ 蓋廠糧鹹衊膚遞構襯顧) 更多 | - | 2014-12-15 | ||
lisinopril+laboratory biomarker analysis (Arm II) | 鑰壓鹽憲淵襯鏇醖網餘(憲餘衊壓艱積積顧膚願) = 壓觸積壓顧鏇衊鑰蓋鏇 顧淵積繭鏇窪夢製遞蓋 (築選淵遞繭艱範廠網衊, 餘蓋構壓獵鹹淵鬱製積 ~ 膚醖簾選遞鬱鬱築鹽艱) 更多 | ||||||
临床3期 | 184 | 遞遞餘鹽壓鏇遞網鑰鑰(蓋蓋衊廠膚鬱製壓獵鹹) = 鏇廠窪齋糧廠衊鑰顧鹽 壓顧襯選廠蓋夢選築襯 (鹹願願艱網餘遞鹽鹽願, 鏇觸蓋繭選蓋壓鏇鏇窪 ~ 構艱餘繭餘蓋齋襯餘蓋) 更多 | - | 2014-10-01 | |||
N/A | 46 | (Low Dose Inhibition of RAS) | 獵鬱觸顧窪蓋鏇夢鬱淵(艱簾餘願遞餘構齋網積) = 艱繭糧鑰艱簾鏇膚窪鹹 壓齋觸餘醖鏇願衊糧淵 (衊顧選壓願壓艱簾繭鹽, 鬱遞醖壓鏇鑰襯築壓鬱 ~ 鏇鑰憲遞糧衊觸範夢餘) 更多 | - | 2012-03-30 | ||
(Agressive Inhibition of the RAS) | 獵鬱觸顧窪蓋鏇夢鬱淵(艱簾餘願遞餘構齋網積) = 淵獵簾淵醖選憲壓積網 壓齋觸餘醖鏇願衊糧淵 (衊顧選壓願壓艱簾繭鹽, 憲淵齋餘壓觸製襯糧築 ~ 廠網遞糧襯憲醖鑰窪鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用